• News
  • Media
  • Conferences
  • Publications
  • Events
  • CE
  • Resources
  • Subscribe
Opinion|Videos|January 22, 2025

Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.

Episodes in this series

Video content above is prompted by the following:

  1. How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
    1. Include in your discussion the EASL 2024 abstract.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!

Related Content